Quickfire Q&A delivers in-person insights from congresses, bringing together expert perspectives on the studies and data shaping clinical practice.
In this episode, recorded at the European Hematology Association (EHA) 2026 Congress, we speak to Karin Smedby about the latest developments in lymphoma, including new data in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma, emerging approaches to minimal residual disease (MRD) assessment, and the evolving role of central nervous system (CNS) prophylaxis.
Key topics discussed include:
- DLBCL: New progression-free survival data and the potential for future practice change
- Follicular lymphoma: Strong results with epcoritamab plus R2
- MRD: Promising advances in disease monitoring
- CNS prophylaxis: New evidence challenging its role in high-risk DLBCL
Disclosure: Smedby has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead, AbbVie, and Incyte, with payment to the institution.
Read the latest issue of EMJ Hematology for more expert insights and highlights from EHA 2026.
